These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 30173226)

  • 1. Heterogenous expression of ERG oncoprotein in Malaysian men with adenocarcinoma of the prostate.
    Tan JSJ; Ong KC; Ong DBL; Razack A; Lim J; Yunus R; Sundram M; Rhodes A
    Malays J Pathol; 2018 Aug; 40(2):103-110. PubMed ID: 30173226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
    Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
    Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of ERG versus AMACR expression in diagnosis of minimal adenocarcinoma of the prostate in needle biopsy tissue.
    Andrews C; Humphrey PA
    Am J Surg Pathol; 2014 Jul; 38(7):1007-12. PubMed ID: 24705308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
    Warrick JI; Humphrey PA
    Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERG oncoprotein expression in prostatic acinar adenocarcinoma; clinicopathologic significance.
    Hashmi AA; Khan EY; Irfan M; Ali R; Asif H; Naeem M; Nisar L; Faridi N; Khan A; Edhi MM
    BMC Res Notes; 2019 Jan; 12(1):35. PubMed ID: 30658688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
    Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
    Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relevance of ERG immunoexpression intensity for prostatic adenocarcinoma in radical prostatectomy of 635 samples.
    Feitosa PMFA; Hirth CG; Silva-Fernandes IJL; Dornelas CA
    APMIS; 2023 Sep; 131(9):465-471. PubMed ID: 37439391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance and EZH2, ERG and SPINK1 protein expression in pure and mixed ductal adenocarcinoma of the prostate.
    Patil PA; McKenney JK; Reynolds JP; Przybycin CG; Magi-Galluzzi C
    Histol Histopathol; 2019 Apr; 34(4):381-390. PubMed ID: 30246858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
    Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
    Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma.
    Schneider TM; Osunkoya AO
    Mod Pathol; 2014 Aug; 27(8):1174-8. PubMed ID: 24406865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic features of Annexin A2 expression in prostate cancer.
    Tan SH; Young D; Chen Y; Kuo HC; Srinivasan A; Dobi A; Petrovics G; Cullen J; Mcleod DG; Rosner IL; Srivastava S; Sesterhenn IA
    Pathology; 2021 Feb; 53(2):205-213. PubMed ID: 32967771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients.
    Tsourlakis MC; Stender A; Quaas A; Kluth M; Wittmer C; Haese A; Graefen M; Steurer S; Simon R; Korbel J; Weischenfeldt J; Huland H; Sauter G; Schlomm T; Minner S
    BMC Cancer; 2016 Aug; 16():641. PubMed ID: 27530104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.
    Berg KD; Brasso K; Thomsen FB; Røder MA; Holten-Rossing H; Toft BG; Iversen P; Vainer B
    J Clin Pathol; 2015 Oct; 68(10):788-94. PubMed ID: 26060265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.
    Kimura T; Furusato B; Miki J; Yamamoto T; Hayashi N; Takahashi H; Kamata Y; van Leenders GJ; Visakorpi T; Egawa S
    Pathol Int; 2012 Nov; 62(11):742-8. PubMed ID: 23121605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.
    Haffner MC; Weier C; Xu MM; Vaghasia A; Gürel B; Gümüşkaya B; Esopi DM; Fedor H; Tan HL; Kulac I; Hicks J; Isaacs WB; Lotan TL; Nelson WG; Yegnasubramanian S; De Marzo AM
    J Pathol; 2016 Jan; 238(1):31-41. PubMed ID: 26331372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
    Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
    Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.
    Raymundo EM; Diwa MH; Lapitan MC; Plaza AB; Sevilleja JE; Srivastava S; Sesterhenn IA
    Prostate; 2014 Aug; 74(11):1079-85. PubMed ID: 24909781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
    Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
    Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas.
    Downes MR; Satturwar S; Trudel D; van der Kwast TH
    Pathol Res Pract; 2017 Jan; 213(1):34-38. PubMed ID: 27913052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.